Clarity Pharmaceuticals Ltd
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Clarity Pharmaceuticals Ltd
RECRUITINGPhase 1 / Phase 2NCT04868604
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant...
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Clarity Pharmaceuticals LtdEnrolling: 547 locations
Prostatic Neoplasms, Castration-Resistant
RECRUITINGPhase 3NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate...
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Sponsor: Clarity Pharmaceuticals LtdEnrolling: 22020 locations
Prostate CancerProstate Cancer Patients With Detectable PSA Following ProstatectomyProstate Cancer Recurrent+3